Cariprazine: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Cariprazine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is schizophrenia, which is supported by a licence in another country.
Quick overview
Item
Content
New predicted indications
None (all traceable model candidates are known uses)
Known uses among model candidates
1
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses among the model’s candidates
Approved (supported by a licence or label)
Indication
Source
schizophrenia
Licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
none
Australia Market Information
Licence
Product
Dosage form
Status
12619E
Reagila
Capsule 3 mg
Valid
Safety Considerations
Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.
Drug Interactions (100 interactions recorded; the first 20 reviewed are shown, all from DDInter):
Interactions with antidiabetic agents are notable because cariprazine may affect glucose control. The major interactions reflect CNS depression (morphine) and CYP-mediated effects (clarithromycin, bupropion). Both need to be checked against the PI.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.